I have SMA. Critics of the $2 million new therapy are missing the point
I was perplexed and disappointed that the recent approval of Novartis’ gene therapy Zolgensma was immediately overshadowed by outrage over the drug’s price.
Related Articles
How efforts to cancel medical debt could wind up benefitting hospitals
Hospitals could benefit from Vice President Harris’ plan to cancel medical debt. Sign up for STAT’s twice-weekly newsletter about the politics and policy of health…
A rare disease program, portrayed as both lifeline and pharma handout, is set to expire
Advocates for people with rare diseases say a government voucher program has been crucial to pursuing treatments. That program is due to sunset at the…
Moderna touts research progress as it cuts R&D spending by $1.1 billion
After being criticized for profligate post-pandemic spending, the company is “pacing” itself to focus on launches of key medicines.
Apple will offer millions of AirPod users a hearing aid. Can it convince them to use it?
AirPods Pro earbuds will soon double as hearing aids for people with mild to moderate hearing loss.
Gilead’s twice-yearly antiviral protects against HIV infection in second large trial
Gilead said Thursday that its twice-yearly antiviral reduced the risk of HIV infections by 96% compared to an expected rate of infection in a second
2024 STAT Summit
The STAT Summit is back in Boston October 16 & 17, 2024 — this year we’re examining change in medicine, why it’s so hard, &…
2024 STAT Summit Agenda
The 2024 STAT Summit agenda features high-profile panelists discussing topics ranging from drug development to courting biotech investors. Come join us!
‘Put him in jail.’ Steward CEO de la Torre skips hearing, now Congress is poised to hold him in contempt
At a congressional hearing, nurses detailed mismanagement of the Steward Health Care, now in bankruptcy. Despite a subpoena, de la Torre didn’t appear.
Embedded Bias
STAT series ‘Embedded Bias’ explores how race-based clinical algorithms became pervasive in medicine, and why racial factors have been difficult to remove.
Cause of Missouri H5 bird flu case remains a mystery, CDC says
Disease investigators have not been able to determine how a person in Missouri with no known exposures to animals or poultry became infected with an…